ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chenpon Pharmaceutical, AstraZeneca and Chiesi Farmaceutici side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Chenpon Pharmaceutical×AstraZeneca×Chiesi Farmaceutici×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Chenpon PharmaceuticalAstraZenecaChiesi Farmaceutici
studies on the registry34,197299
open to participants now029837
phase 3 studies under way02007
reach primary completion within a year016811
programswith a study of their own in two years4119+5 named only15

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChenpon PharmaceuticalAstraZenecaChiesi Farmaceutici
Phase 1

Chenpon Pharmaceutical: 1 of its 4 programs at phase 1

  1. Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosolphase 1
25%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Chiesi Farmaceutici: 2 of its 15 programs at phase 1

  1. CHF10073phase 1
  2. CHF10136phase 1
13%
Phase 2

Chenpon Pharmaceutical: 1 of its 4 programs at phase 2

  1. umeclidinium bromidephase 2
25%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Chiesi Farmaceutici: 2 of its 15 programs at phase 2

  1. CHF-6467phase 2
  2. CHF10067phase 2
13%
Phase 3

Chenpon Pharmaceutical: 2 of its 4 programs at phase 3

  1. Budesonidephase 3
  2. formoterolphase 3
50%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Chiesi Farmaceutici: 6 of its 15 programs at phase 3

  1. florensocatibphase 3
  2. episalvanphase 3
  3. birch triterpenesphase 3
  4. CHF5993 100/6/12.5 μg pMDI HFA-152aphase 3
  5. Experimental: Participant Group CHF 5993 pMDI HFA-152aphase 3

and 1 more — sign in to see them all

40%
Approved, new studies00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Chiesi Farmaceutici: 5 of its 15 programs at approved, new studies

  1. CHF5993approved, new study
  2. sebetralstatapproved, new study
  3. Foster® 200/6 pMDI (BDP/FF-200/6 µg)approved, new study
  4. Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation)approved, new study
  5. ff-200approved, new study
33%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Chenpon Pharmaceutical0 readouts · 0 phase 3············
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Chiesi Farmaceutici4 readouts · 0 phase 3·

Chiesi Farmaceutici, Dec ’26: 1 program whose next study reaches primary completion

  1. florensocatibphase 3 · Dec 9 · NCT07683793
·

Chiesi Farmaceutici, Feb ’27: 1 program whose next study reaches primary completion

  1. CHF-6467phase 2 · Feb 28 · NCT07163182
···

Chiesi Farmaceutici, Jun ’27: 1 program whose next study reaches primary completion

  1. CHF5993approved, new study · Jun 3 · NCT07301736
·

Chiesi Farmaceutici, Aug ’27: 1 program whose next study reaches primary completion

  1. CHF10073phase 1 · Aug 0 · NCT07876284
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Chenpon Pharmaceutical

New programs 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Chiesi Farmaceutici

New programs 1

  • CHF10136phase 1 · first study · Sep 18 · Asthma

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionChenpon PharmaceuticalAstraZenecaChiesi Farmaceutici
Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Chiesi Farmaceutici in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. tanimilastphase 3
  2. CHF5993approved, new study

Their studies: Chiesi Farmaceutici’s studies of Pulmonary Disease, Chronic Obstructive in search

Bronchitis, Chronicall three · compare here

Chenpon Pharmaceutical in Bronchitis, Chronic: 1 program

  1. formoterolphase 3

Their studies: Chenpon Pharmaceutical’s studies of Bronchitis, Chronic in search

AstraZeneca in Bronchitis, Chronic: 2 programs

  1. tozorakimabphase 3
  2. formoterolapproved, new study

Their studies: AstraZeneca’s studies of Bronchitis, Chronic in search

Chiesi Farmaceutici in Bronchitis, Chronic: 1 program

  1. tanimilastphase 3

Their studies: Chiesi Farmaceutici’s studies of Bronchitis, Chronic in search

Idiopathic Pulmonary Fibrosis2 of 3 · compare here–

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Chiesi Farmaceutici in Idiopathic Pulmonary Fibrosis: 2 programs

  1. CHF10067phase 2
  2. CHF10073phase 1

Their studies: Chiesi Farmaceutici’s studies of Idiopathic Pulmonary Fibrosis in search

Asthma, Exercise-Induced2 of 3 · compare here

Chenpon Pharmaceutical in Asthma, Exercise-Induced: 1 program

  1. formoterolphase 3

Their studies: Chenpon Pharmaceutical’s studies of Asthma, Exercise-Induced in search

AstraZeneca in Asthma, Exercise-Induced: 1 program

  1. formoterolapproved, new study

Their studies: AstraZeneca’s studies of Asthma, Exercise-Induced in search

–
Bronchiectasis2 of 3 · compare here–

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

Chiesi Farmaceutici in Bronchiectasis: 1 program

  1. florensocatibphase 3

Their studies: Chiesi Farmaceutici’s studies of Bronchiectasis in search

Colitis, Ulcerative2 of 3 · compare here

Chenpon Pharmaceutical in Colitis, Ulcerative: 1 program

  1. Budesonidephase 3

Their studies: Chenpon Pharmaceutical’s studies of Colitis, Ulcerative in search

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

–
Eosinophilic Esophagitis2 of 3 · compare here

Chenpon Pharmaceutical in Eosinophilic Esophagitis: 1 program

  1. Budesonidephase 3

Their studies: Chenpon Pharmaceutical’s studies of Eosinophilic Esophagitis in search

AstraZeneca in Eosinophilic Esophagitis: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Eosinophilic Esophagitis in search

–
Glomerulonephritis, IGA2 of 3 · compare here

Chenpon Pharmaceutical in Glomerulonephritis, IGA: 1 program

  1. Budesonidephase 3

Their studies: Chenpon Pharmaceutical’s studies of Glomerulonephritis, IGA in search

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetChenpon PharmaceuticalAstraZenecaChiesi Farmaceutici
NR3C1BudesonideruleBudesoniderule–
A target, or a pathogen for a vaccine, known for: Chenpon Pharmaceutical 2 of 4 · AstraZeneca 68 of 119 · Chiesi Farmaceutici 1 of 15 programs (32 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).